Zhuangjun Si, MD
Glaucoma Specialist · Wheaton, ILNPI 1932605672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by NEW World Medical,inc. at 27.6% of the total. Reporting peaked in 2024 at $1,363 and has fallen 66.2% since, to $461 in 2025.
Across 52 payments — averaging $69.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$991
- AbbVie$726
- Alcon$450
- Regeneron Healthcare Solutions, Inc.$276
- Glaukos Corporation$191
- Mallinckrodt Hospital Products Inc.$144
- plus $818 from 11 others
What the payments were for
- Food & beverage$3,596100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 14 | $991 |
| AbbVie(2 entities) | 11 | $726 |
| Alcon | 7 | $450 |
| Regeneron Healthcare Solutions, Inc. | 4 | $276 |
| Glaukos Corporation | 2 | $191 |
| Mallinckrodt Hospital Products Inc. | 1 | $144 |
| Novartis | 2 | $141 |
| Sight Sciences, Inc. | 1 | $139 |
| Eyepoint US, Inc. | 1 | $124 |
| Alimera Sciences, Inc. | 1 | $121 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $109 |
| Astellas Pharma US Inc | 2 | $47 |
| Iridex Corporation | 1 | $41 |
| Amgen | 1 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Thea Pharma Inc. | 1 | $23 |
| Gilead | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$752
- Clearpath$752
- Ahmed Glaucoma Valve$752
- Streamline$752
- OZURDEX$262
- XEN GLAUCOMA TREATMENT SYSTEM$231
- Tecnis IOL$218
- Via360$171
- Clareon$146
- ACTHAR$144
- OMNI(R) SURGICAL SYSTEM (US)$139
- Centurion$126
- YUTIQ$124
- BEOVU$124
- EYLEA$122
- Iluvien$121
- SIMBRINZA$115
- Rocklatan$115
- Rhopressa$115
- VERITAS Vision System$109
How this compares
Too few glaucoma specialist providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 50 | $24,787 |
| LumiganBimatoprost | 36 | $19,097 |
| RhopressaNetarsudil Mesylate | 28 | $14,973 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $14,178 |
| VyzultaLatanoprostene Bunod | 23 | $13,037 |
| Ketorolac Tromethamine | 238 | $9,704 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 29 | $6,828 |
| Prednisolone Acetate | 211 | $6,675 |
| Latanoprost | 510 | $6,012 |
| Travatan ZTravoprost | 12 | $5,775 |
| Brimonidine Tartrate | 154 | $4,731 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 265 | $4,108 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $3,257 |
| Timolol Maleate | 88 | $3,245 |
| MoxifloxacinMoxifloxacin Hcl | 174 | $2,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $726 | $33,27677 claims |
| AlconSimbrinza | $450 | $6,82829 claims |
| NovartisTravatan Z | $141 | $5,77512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Wheaton
- Jeremy WingardWheaton$45K
- Ruth WilliamsWheaton$15K
- Edward SungWheaton$1K
- Frini MakadiaWheaton$833
- Deepak EdwardChicago$53K
- Jessica KangChicago$37K
- David HillmanChicago$10K
- Ayesha BadarMaywood$5K
- Rebecca SarranChicago$3K
- Nandita AnandGlenview$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.